Market capitalization | $136.78b |
Enterprise Value | $147.56b |
P/E (TTM) P/E ratio | 40.03 |
EV/FCF (TTM) EV/FCF | 52.64 |
EV/Sales (TTM) EV/Sales | 6.90 |
P/S ratio (TTM) P/S ratio | 6.39 |
P/B ratio (TTM) P/B ratio | 6.92 |
Dividend yield | 0.85% |
Last dividend (FY23) | $3.05 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
32 Analysts have issued a Stryker forecast:
32 Analysts have issued a Stryker forecast:
Jun '24 |
+/-
%
|
||
Revenue | 21,389 21,389 |
10%
10%
|
|
Gross Profit | 13,092 13,092 |
13%
13%
|
|
EBITDA | 5,602 5,602 |
12%
12%
|
EBIT (Operating Income) EBIT | 4,572 4,572 |
15%
15%
|
Net Profit | 3,448 3,448 |
27%
27%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Stryker Corp. engages in providing medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The Medsurg segment deals with surgical equipment and navigation systems, endoscopy, patient handling, and reprocessed medical devices. The Neurotechnology and Spine segment pertains to spinal implants and neurovascular products. The company was founded by Homer H. Stryker in 1941 and is headquartered in Kalamazoo, MI.
Head office | United States |
CEO | Kevin Lobo |
Employees | 52,000 |
Founded | 1941 |
Website | www.stryker.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.